Drug intelligence / Profile preview

acetazolamide + platinum + etoposide

Development stage: Unknown
Lead developer: Pfizer
Modality: Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
Administration: Oral, Intravenous

Overview

This combination involves **acetazolamide**, a carbonic anhydrase inhibitor; **platinum** compounds, which are DNA alkylating agents; and **etoposide**, a topoisomerase II inhibitor. The combination is being studied for its potential in treating various cancers, including small cell lung cancer, by enhancing the effects of chemotherapy and radiotherapy.

Targets

CA (Carbonic anhydrase)DNATOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on acetazolamide + platinum + etoposide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on acetazolamide + platinum + etoposide.

Explore the full profile